Bicara Therapeutics BCAX Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's accrued manufacturing costs?
- Bicara Therapeutics (BCAX) reported accrued manufacturing costs of $1.91M in Q1 2026.
- How has Bicara Therapeutics's accrued manufacturing costs changed year-over-year?
- Bicara Therapeutics's accrued manufacturing costs increased by 14.1% year-over-year, from $1.68M to $1.91M.
- What is the long-term trend for Bicara Therapeutics's accrued manufacturing costs?
- Over 2 years (2023 to 2025), Bicara Therapeutics's accrued manufacturing costs has grown at a 70.1% compound annual growth rate (CAGR), from $1.74M to $5.04M.